Preview of ESC conference starting this weekend: http://finance.yahoo.com/news/Data-may-prove-Bristol-Pfizer-rb-951666488.html?x=0&.v=1 Roche’s Dalcetrapib and PFE/BMY’s Eliquis will probably the two most watched presentations.